The firm said its remaining employees will focus on developing the pol theta inhibitor RP-3467 and the PLK4 inhibitor RP-1664.

The company said the move demonstrates the board of directors' confidence in the potential of its PARP1/2 inhibitor in ovarian cancer.

ABI-201 is undergoing IND-enabling studies and uses the same capsid as the firm's clinical-stage gene therapy candidate for wet AMD.